$CDXS
CODEXIS, INC. Stock $cdxs

$cdxs Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000120037516000061 Filed on May 09, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$7.996M	$6.798M
YoY Change	17.62%	-3.9%
Cost Of Revenue	$2.489M	$1.456M
YoY Change	70.95%	-42.31%
Gross Profit	$5.507M	$5.342M
YoY Change	3.09%	17.41%
Gross Profit Margin	68.87%	78.58%
Selling, General & Admin	$6.802M	$5.578M
YoY Change	21.94%	-8.74%
% of Gross Profit	123.52%	104.42%
Research & Development	$5.686M	$5.293M
YoY Change	7.42%	9.5%
% of Gross Profit	103.25%	99.08%
Depreciation & Amortization	$465.0K	$558.0K
YoY Change	-16.67%	-45.08%
% of Gross Profit	8.44%	10.45%
Operating Expenses	$14.98M	$12.33M
YoY Change	21.5%	-8.49%
Operating Profit	-$6.981M	-$5.529M
YoY Change	26.26%	-13.56%
Interest Expense	$20.00K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$3.000K	$25.00K
YoY Change	-88.0%	-78.81%
Pretax Income	-$6.963M	-$5.550M
YoY Change	25.46%	-14.68%
Income Tax	$11.00K	$12.00K
% Of Pretax Income
Net Earnings	-$6.974M	-$5.562M
YoY Change	25.39%	-12.75%
Net Earnings / Revenue	-87.22%	-81.82%
Basic Earnings Per Share
Diluted Earnings Per Share	-$173.9K	-$143.4K
COMMON SHARES
Basic Shares Outstanding	40.47M shares	39.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.20M	$22.20M
YoY Change	0.0%	-8.13%
Cash & Equivalents	$22.16M	$22.16M
Short-Term Investments
Other Short-Term Assets	$1.200M	$1.300M
YoY Change	-7.69%	-58.06%
Inventory	$1.021M	$992.0K
Prepaid Expenses
Receivables	$4.352M	$3.215M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$28.78M	$27.63M
YoY Change	4.14%	-19.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.756M	$3.499M
YoY Change	-21.23%	-52.69%
Goodwill	$3.241M	$3.241M
YoY Change	0.0%	0.0%
Intangibles	$1.968M	$5.342M
YoY Change	-63.16%	-38.71%
Long-Term Investments	$1.500M	$700.0K
YoY Change	114.29%	-50.0%
Other Assets	$202.0K	$284.0K
YoY Change	-28.87%	36.54%
Total Long-Term Assets	$10.41M	$13.79M
YoY Change	-24.48%	-36.51%
TOTAL ASSETS
Total Short-Term Assets	$28.78M	$27.63M
Total Long-Term Assets	$10.41M	$13.79M
Total Assets	$39.19M	$41.42M
YoY Change	-5.39%	-25.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.850M	$1.952M
YoY Change	46.0%	-44.02%
Accrued Expenses	$3.224M	$2.065M
YoY Change	56.13%	-23.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.48M	$11.87M
YoY Change	38.87%	-9.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.458M	$4.154M
YoY Change	-40.83%	-15.22%
Total Long-Term Liabilities	$2.458M	$4.154M
YoY Change	-40.83%	-15.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.48M	$11.87M
Total Long-Term Liabilities	$2.458M	$4.154M
Total Liabilities	$18.94M	$16.02M
YoY Change	18.21%	-17.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$290.5M	-$281.5M
YoY Change	3.19%	6.94%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.11M	$21.62M
YoY Change
Total Liabilities & Shareholders Equity	$39.19M	$41.42M
YoY Change	-5.39%	-25.98%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$6.974M	-$5.562M
YoY Change	25.39%	-12.75%
Depreciation, Depletion And Amortization	$465.0K	$558.0K
YoY Change	-16.67%	-45.08%
Cash From Operating Activities	$219.0K	-$3.848M
YoY Change	-105.69%	60.0%
INVESTING ACTIVITIES
Capital Expenditures	$265.0K	$52.00K
YoY Change	409.62%	147.62%
Acquisitions
YoY Change
Other Investing Activities	$30.00K	$10.00K
YoY Change	200.0%	-99.72%
Cash From Investing Activities	-$238.0K	-$47.00K
YoY Change	406.38%	-101.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.091M	-$433.0K
YoY Change	151.96%	157.74%
NET CHANGE
Cash From Operating Activities	$219.0K	-$3.848M
Cash From Investing Activities	-$238.0K	-$47.00K
Cash From Financing Activities	-$1.091M	-$433.0K
Net Change In Cash	-$1.110M	-$4.328M
YoY Change	-74.35%	-518.97%
FREE CASH FLOW
Cash From Operating Activities	$219.0K	-$3.848M
Capital Expenditures	$265.0K	$52.00K
Free Cash Flow	-$46.00K	-$3.900M
YoY Change	-98.82%	60.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	cdxs	Lease Incentive Obligation Noncurrent LeaseIncentiveObligationNoncurrent	1310000	USD
CY2016Q1	cdxs	Lease Incentive Obligation Noncurrent LeaseIncentiveObligationNoncurrent	1204000	USD
CY2015Q1	cdxs	Longterm Lease Incentive LongtermLeaseIncentive	106000	USD
CY2016Q1	cdxs	Longterm Lease Incentive LongtermLeaseIncentive	106000	USD
CY2016Q1	cdxs	Maturity Date Of Highly Liquid Investments MaturityDateOfHighlyLiquidInvestments	P3M
CY2015Q4	cdxs	Numberof Marketable Securities In Unrealized Loss Position NumberofMarketableSecuritiesInUnrealizedLossPosition	0	security
CY2016Q1	cdxs	Numberof Marketable Securities In Unrealized Loss Position NumberofMarketableSecuritiesInUnrealizedLossPosition	0	security
CY2016Q1	cdxs	Operating Leases Future Minimum Payments Duein Five Yearsand Thereafter OperatingLeasesFutureMinimumPaymentsDueinFiveYearsandThereafter	236000	USD
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001200375
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40788170	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	CODEXIS INC
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3399000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2850000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7329000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4352000	USD
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2013000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3224000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32215000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32680000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	405000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	315000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305981000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	306279000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	421000	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	421000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	844000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	844000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7199000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6650000	shares
CY2015Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	368000	USD
CY2016Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	400000	USD
CY2015Q4	us-gaap	Assets Assets	44647000	USD
CY2016Q1	us-gaap	Assets Assets	39188000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	32839000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	28775000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12669000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12589000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	986000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	896000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11683000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11693000	USD
CY2016Q1	us-gaap	Cash Cash	11100000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26487000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22159000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23273000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22163000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4328000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1110000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40636000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41081000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40343000	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40788000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5546000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7064000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1456000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2489000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6098000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6105000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3120000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2929000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	558000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	465000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3331000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4305000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18966000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19810000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1968000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21778000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21778000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2812000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1968000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	27000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	3241000	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q1	us-gaap	Incentive From Lessor IncentiveFromLessor	1600000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5550000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6963000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2731000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-395000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-655000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2977000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	723000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-184000	USD
CY2015Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	654000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	974000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-403000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	30000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-557000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1172000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-109000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2812000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1968000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	730000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	712000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	992000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	1021000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	262000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	272000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	37000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	USD
CY2016Q1	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	10000000	shares
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	800000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44647000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39188000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14841000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16484000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	12327000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000	USD
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1549000	USD
CY2016Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1459000	USD
CY2016Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11100000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-433000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1091000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-238000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3848000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	219000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-5562000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-6974000	USD
CY2016Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	operating_segment
CY2016Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	reporting_unit
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	14977000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5529000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6981000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10595000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	2500000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2818000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2736000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2677000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2128000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	200000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	200000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	310000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	202000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	16000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-90000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	8000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2497000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2458000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2015Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	557000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1098000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	265000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1245000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1239000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	27000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	124000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35324000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35436000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3109000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2756000	USD
CY2015Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2197000	USD
CY2016Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	3534000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5293000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5686000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	787000	USD
CY2016Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	787000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283511000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-290485000	USD
CY2015Q1	us-gaap	Revenues Revenues	6798000	USD
CY2016Q1	us-gaap	Revenues Revenues	7996000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1525000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	722000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	3076000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	3740000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5578000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6802000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1285000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1389000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.93
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	64263	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4466	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	22879000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	16113000	USD
CY2015Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	16000	USD
CY2016Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-90000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38779000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40072000	shares
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments that are potentially subject to concentration of credit risk primarily consist of cash equivalents, short term investments, accounts receivable, marketable securities and restricted cash. We invest cash that is not required for immediate operating needs principally in money market funds.</font></div></div>
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these notes to the condensed consolidated financial statements, the "Company," "we," "us," and "our" refer to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We develop biocatalysts for the pharmaceutical and fine chemicals markets. Our proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biocatalysts are enzymes that initiate and/or accelerate chemical reactions. Manufacturers have historically used naturally occurring biocatalysts to produce many goods used in everyday life. However, inherent limitations in naturally occurring biocatalysts have restricted their commercial use. Our proprietary CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform, which introduces genetic mutations into microorganisms in order to give rise to changes in enzymes that they produce, is able to overcome many of these limitations, allowing us to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once potentially beneficial mutations are identified through this proprietary process, combinations of these mutations can then be tested until variant enzymes have been created that exhibit marketable performance characteristics superior to competitive products. This process allows for continuous, efficient improvements to the performance of enzymes. In the past, we implemented the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform through paid collaborations with our customers. In July 2014, we entered into our first license agreement pursuant to which we granted a license to a global pharmaceutical company to use the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform for its internal development purposes. In August 2015, we entered into a license agreement involving the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform with a second global pharmaceutical company and we continue to pursue licensing opportunities with additional customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> We have commercialized our technology and products in the pharmaceuticals market, which is our primary business focus. Our customers, which include several large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also use our technology to develop biocatalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food, animal feed, flavors, fragrances, and agricultural chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also using our technology to develop an early stage, novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are actively collaborating with new and existing customers in the pharmaceutical and other markets.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of investment securities and marketable securities, assets held for sale, intangible assets, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001200375-16-000061-index-headers.html	Edgar Link	pending
0001200375-16-000061-index.html	Edgar Link	pending
0001200375-16-000061.txt	Edgar Link	pending
0001200375-16-000061-xbrl.zip	Edgar Link	pending
cdxs-20160331.xml	Edgar Link	completed
cdxs-20160331.xsd	Edgar Link	pending
cdxs-20160331_cal.xml	Edgar Link	unprocessable
cdxs-20160331_def.xml	Edgar Link	unprocessable
cdxs-20160331_lab.xml	Edgar Link	unprocessable
cdxs-20160331_pre.xml	Edgar Link	unprocessable
cdxs_20160331x10q.htm	Edgar Link	pending
cdxs_20160331xex311.htm	Edgar Link	pending
cdxs_20160331xex312.htm	Edgar Link	pending
cdxs_20160331xex321.htm	Edgar Link	pending
exh101lalonde-cocamendment.htm	Edgar Link	pending
exh101lalondecocamend_image1.jpg	Edgar Link	pending
exh102sangster-cocamendment.htm	Edgar Link	pending
exh102sangstercocamen_image1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXS
CODEXIS, INC. Stock $cdxs

2016 Q1 Form 10-Q Financial Statement

#000120037516000061 Filed on May 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS CODEXIS, INC. Stock $cdxs

2016 Q1 Form 10-Q Financial Statement

#000120037516000061 Filed on May 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS
CODEXIS, INC. Stock $cdxs